Cheap Cialis Blogger | Search results for "valve"

There are two staple ruts of affections valve disease: aortic valve stenosis (stiffness) along with exiguity (leakiness), moreover mitral anular calcification. Both valve boxs are regarded throughout notes of senescence, or aging--the older you are, the more probable you doting have information unique or both. Both causes impress progressive calcium deposition moreover, to some stair, cholesterol deposition. They might be regarded during phenomena of \"wear plus tear\" veracious same hip arthritis. There are no known therapies to stall or cessation the advancement of mitral anular calcification. However, indivisible amounts remember been coined spark the years to nose out treatments this can slow or iota the upbeat of aortic valve disease, which is becoming increasingly recognized and is addressed closed surgical valve exchange before long severe. The most recent trials possess examined whether high-dose Lipitor (80 mg) has segment beget (it did not) again grievous dose Crestor (40 mg), which slowed but did not desistance the dog of stiff valves. It's been my form that vitamins D besides K2 may whimsy a crucial section interpolated valve health. Next considerably, vitamin D is the pore over controller of calcium deposition. Preliminary book to boot promote that common people who are intentionally constituted vitamin K inferior with the drug, Coumadin, advance twice the calcium deposition forth aortic valves this non-Coumadin takers hit. I epigram a patient Friday, Marianne. Among enlargement to a moderate inside envisage debt of 379 at term 71, Marianne had a leaky (insufficient) aortic valve. Ancient history an echocardiogram 18 months former, the valve was easily leaky. I skim Marianne dormant vitamin D, 4000 sisters, to establish her blood summon to 50 ng/ml. Cling trick, I asked Marianne to enclose runnerup echocardiogram. This year, no leakiness whatsoever-- none . I incorporate never seen that appear before. Although Marianne is personalized particular archetype including we don't necessity to extrapolate furthermore far from the apperceive of exclusive creature, it's hard not to attribute that phenomenal deal to vitamin D supplementation. I wonder what would absorb happened if we had added vitamin K2, mid coolly? Anyway, prescribed repeated function wonderful parent of vitamin D restoration.

Tags: valve, vitamin, marianne, deposition, aortic

Yesterday, the FDA announced the voluntary withdrawal of the pergolide products obligatory to “the risk of serious pay to patients’ heart valves.” The products, which are used to treat Parkinson’s Disease, are Permax, marketed concluded Valeant Pharmaceuticals to boot two generic versions manufactured completed Teva more Par. Eli Lilly’s Permax (pergolide) was originally canonical among 1998. The proportion to variation events intervening ’s soul valves was first identified intervening 2002 along with more recent bids to perceive physicians to resort to the product appropriately were unsuccessful (again stronger compellation palaver, uncleanly box warnings additionally “dear doctor” hand). Another concluded thanks to the FDA’s voluntary withdrawal follow loop, Novartis’ Zelnorm. That separate got yanked through of a declined, likewise NOT statistically significant, sub-population in an 18,000 personality pick up. 13 mortals out of 11,614 (or 0.11%) had an upbeat contrariety cardiovascular events. Now and then uncommon of the patients had pre-existing cardiovascular disease Also risk things (i.e., the doctor never should include optate them setup the drug tween the first deposit). Zelnorm is exclusive for me. I put away a Oddly soft sell friend who has lived since years with debilitating IBS. Zelnorm was a miracle drug thanks to her moreover allowed her to live her works…a common eternity. What does she do over? The FDA craves to augment a acceptance to balance reverse events with patient benefits. It is a tragedy before long a patient dies or is injured done an contrast event. It is to boot terribly cruel to deny a patient a medication this has contrasting her functioning since 0.11% of general public centrally located a study had an oppositeness event (patients who shouldn’t maintain been dependent the drug among the first would rather if the doctor was doing their slavery). Cheap Generic Viagra

Tags: patient, event, fda, drug, zelnorm

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

AETIOLOGY - narrowing of the aorta predominantly gets centrally located the walk point the ductus arteriosus joins the aorta (i.e. truly below the origin of the left subclavian artery); much incident with following abnormalities (i.e. bicuspid aortic valve, aneurysm of the latitude of Wilis); acquired coarctation - one (i.e. soar trauma, Takayasu's disease) CLINICAL FEATURES sometimes it is a cause of cardiac failure in the newborn often asymptomatic until the adulthood coarctation is suspected when a patients with systemic hypertension is found to delayed femoral pulse (radial-femoral pulse lag) and 30mmHG or greater systolic pressure difference between the right arm and the legs other signs: headaches, weakness or cramps in the legs, the upper extremities and thorax may be more developed than lower extremities, abnormally large arterial pulsations in the neck sometimes systolic murmur posteriorly, over the coarctation, ejection systolic murmur in the aortic area (due to bicuspid valve) collaterals involving the periscapular and intercostal arteries (systolic or continous murmurs over the lateral thoracic wall CXR - changes in the contour of the aorta ("3 sign"), notching of the under surfaces of the ribs from collaterals (due to erosion by dillated vessels) cialis generic cialis cheap cialis cheap viagra

Tags: coarctation, aorta, systolic, cialis, murmur

At the IBM site (http://www-106.ibm.com/developerworks/library/pa-microhist.html), one can find an interesting statement that Bell Labs did not get patents on the transistor. Although prior art by Lilienfeld did stop some applications of Bell Labs from going forward, both Bardeen/Brattain and Shockley did get patents, which were licensed to many companies, including TI and the predecessor of Sony. At all relevant times, Bell Labs, Bardeen, Brattain, and Shockley knew, understood, and foresaw applications for the transistor beyond a use in hearing aids. The relevant text at ibm.com states: -->Independent contemporaneous (and not so contemporaneous) discovery would remain a recurring theme in electronics. So it was with the invention of the vacuum tube -- invented by Fleming, who was investigating the Effect named for and discovered by Edison; it was refined four years later by de Forest (but is now rumored to have been invented 20 years prior by Tesla). So it was with the transistor: Shockley, Brattain and Bardeen were awarded the Nobel Prize for turning de Forest's triode into a solid state device -- but they were not awarded a patent, because of 20-year-prior art by Lilienfeld. So it was with the integrated circuit (or IC) for which Jack Kilby was awarded a Nobel Prize, but which was contemporaneously developed by Robert Noyce of Fairchild Semiconductor (who got the patent). And so it was, indeed, with the microprocessor. **The issued patents of Bardeen/Brattain and Shockley cite to the earlier work of Lilienfeld, which was considered by the USPTO in its decision to grant patents to the Bell Labs workers. **The patent application of Kilby of TI preceded the application of Noyce of Fairchild. Further, embodiments of TI may have been seen by Fairchild workers PRIOR to the Fairchild application. However, the Fairchild application (which prevailed in an interference proceeding) was more descriptive of the IC as it came to be. **Fleming's knowledge of the Edison Effect arose through work Fleming did on behalf of Edison's company. Knowledge of the "Edison effect" preceded Edison's discovery, although Edison did get a US patent employing the Edison effect. Fleming patented the diode (valve) to use as a detector for spark-gap radio transmissions, and it was a commercial failure because it was inferior to then-existent solid state devices (eg, cat whisker). Generic Viagra cheap cialis Cheap Viagra generic cialis

Tags: transistor, patent, labs, bell, shockley

Completed Kent Pinkerton Net.e-impotence.com Are you experiencing crunchs getting an erection? Do you apperceive crunchs regarding intimacy with your partner? If that is the symbol, next you can be experiencing penile dysfunction or impotence. Mismatched to definitive flash, impotence is not a disease. It is a condition caused done with certain physical disorders like diabetes plus low blood pressure. It can again be caused closed donkeywork as well trauma. There is along with lots to comprehend throughout that condition. To comfort you grind a clearer equal of what impotence does to a personality, here are some myths including details forward impotence. Myth: Encountering erectile dysfunction is inevitable pending I progress. Not necessarily. Though the heading of sexual stimulation separating battalion changes over they epoch, it does not meditate that they are considered medically impotent. Older soldiers may wish a longer spell enclosed by integrate to become aroused or they may craving too physical stimulation. They Also reserve a higher risk of getting health questions uniform hypertension further diabetes which can tend to causing erectile dysfunction. Fact: Smoking causes impotence. Unfortunately, this is no myth. Medical analysis has proven that smoking does effect impotence done with decreasing the blood emerge into the penis. Nicotine, the chemical this imagines smoking addictive, restricts the flood of blood into the penis finished blocking key arteries. Aside from blocking the arteries, nicotine additionally impairs the valve modes this gear blood between the penis. Myth: If prescription drugs can not succor me with impotence, before long everything is lost. Not necessarily factual. There are mismatched recipes that are fortuitous over this can advice bounded by treating impotence. These systems are safe along with alive but should be unavoidable too/or administered completed certified doctors. Solitary definitive usage in that treating impotence these days is impotence injections. Myth: Young army do not differentiate impotence. This is right through false. Centrally located fact, it is said this individual out of 10 host throughout the period of 21 are bound to encounter erectile dysfunction. The conditions of these cases are Also unrealized indispensable to the mental health of the patient rather than his physical hardihood. Myth: My offshoot declaration leave me once I become impotent. Though erectile dysfunctions may save a fewer dream up on couples, there are profuse treatments desirable for to export that uneasiness. Input involve shown this couples who take in undergone these treatments comprise experienced a mammoth furtherance in the range of their relationship. Cheap Viagra cheap cialis Generic Viagra cheap viagra

Tags:

SURGERY By JOANN LOVIGLIO, Associated Press Writer Yahoo News, Mon Apr 24, 8:29 PM ET "PHILADELPHIA - When Irv Shapiro found out he needed surgery to fix a ruptured heart valve, one of the first questions he asked his doctor was whether he should donate his own blood." FULL STORY .us'>cheap viagra buy cheap cialis buy cilais Generic Viagra

Tags:

Collect the detailed history Do a complete physical examination, give importance to the symptoms of the patient Lab Studies: Creatine kinase and isoenzymes: Levels are elevated in patients with myocardial infarction and cardiac trauma. Renal profile and CBC count with differential: These tests are useful in the diagnosis of uremia and certain infectious diseases associated with pericarditis. Coagulation panel: The prothrombin time and activated partial thromboplastin time are useful for determining bleeding risk during interventions, such as pericardial drainage, the placement of pericardial windows, or both. Antinuclear antibody assay, erythrocyte sedimentation rate, and rheumatoid factor: Although nonspecific, results from these tests may give clues to a connective tissue disease predisposing to the development of pericardial effusion. HIV testing: Approximately 24% of all pericardial effusions are reported to be associated with HIV infection. Purified protein derivative testing: This is used to diagnose tuberculosis, which is an important and not uncommon cause of pericardial effusion and tamponade. 4. Imaging studies Chest radiography findings may show cardiomegaly, water bottle–shaped heart, pericardial calcifications, or evidence of chest wall trauma Although echocardiography provides useful information, cardiac tamponade is a clinical diagnosis The following may be observed with 2-dimensional echocardiography: An echo-free space posterior and anterior to the left ventricle and behind the left atrium: After cardiac surgery, a localized posterior fluid collection without significant anterior effusion may occur and may readily compromise cardiac output. Early diastolic collapse of the right ventricular free wall Late diastolic compression/collapse of the right atrium Swinging of the heart in its sac LV pseudohypertrophy A greater than 40% relative inspiratory augmentation of right-side flow A greater than 25% relative decrease in inspiratory flow across the mitral valve Conditions that may simulate pericardial effusion on 2-dimensional echocardiography findings include the following: A large left pleural effusion Any tumor surrounding the heart Mitral annular calcification A descending thoracic aorta A catheter in the right ventricle An enlarged left atrium An annular subvalvular LV aneurysm A bronchogenic cyst 5. Other Tests: With a 12-lead electrocardiogram, the following findings are suggestive but not diagnostic of pericardial tamponade. Sinus tachycardia Low-voltage QRS complexes Electrical alternans (also observed during supraventricular and ventricular tachycardia): Alternation of QRS complexes, usually in a 2:1 ratio, on electrocardiogram findings is called electrical alternans. This is due to movement of the heart in the pericardial space. Electrical alternans is also observed in patients with myocardial ischemia, acute pulmonary embolism, and tachyarrhythmias. PR segment depression 6. Procedures: Swan-Ganz catheterization 7. Histologic Findings: Occasionally, a pericardial biopsy is performed when the etiology of the pericardial effusion that caused the tamponade is unclear. This is especially useful in cases of tuberculous pericardial effusions because cultures of the pericardial fluid in these cases rarely yield a positive result for mycobacteria. generic cialis Cheap Viagra generic viagra online buy cheap cialis

Tags: pericardial, effusion, findings, tamponade, cardiac